Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Oral corticosteroids for poison ivy dermatitis

John Goodall
CMAJ February 05, 2002 166 (3) 300;
John Goodall
Clinical Assistant Professor Division of Dermatology Faculty of Medicine University of Ottawa Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Michael McKee and colleagues have performed a valuable service by documenting the finding that osteonecrosis of the femoral head may result from a short course of a moderate dose of corticosteroids in relatively young men.1 However, I question their inference in a subsequent letter to the editor that oral corticosteroids are not an appropriate treatment for poison ivy.2

Poison ivy dermatitis, although self- limiting, may persist for 2 months or more. Intensely pruritic blisters and dermatitis may cover more than 50% of the body surface and involve areas that cause particular discomfort or embarrassment such as the genitals, face, hands and feet. If untreated, poison ivy dermatitis can result in prolonged absence from work and many sleepless nights. Mild to moderate cases can be treated with local therapy, but the only effective treatment for severe cases is systemic corticosteroids. Use of a potentially toxic therapy such as oral corticosteroids may in fact be more appropriate for a self-limiting condition than for a chronic condition that may recur after the therapy is discontinued.

It would be helpful if the incidence of avascular necrosis resulting from corticosteroid therapy could be more precisely defined. Do the authors have any suggestions why avascular necrosis does not seem to develop in women or men outside of the 20–41-year age range following short-term corticosteroid therapy? Are a significant majority of the authors' patients men who are 20–41 years old? Does alcoholism increase the risk of osteonecrosis with short-term corticosteroid therapy? One of their 3 patients who had poison ivy dermatitis was also an alcoholic and did not develop pain from osteonecrosis until 23 months after his oral corticosteroid therapy.1

I continue to prescribe oral corticosteroids for patients with severe progressive poison ivy dermatitis. I continue to warn them of the potential side effects, including the risk of avascular necrosis. Any further information to precisely define the risk would be of great service to my patients.

References

  1. 1.↵
    McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ 2001; 164(2):205-6.
    OpenUrlFREE Full Text
  2. 2.↵
    McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Corticosteroids and avascular necrosis of the femoral head [letter]. CMAJ 2001; 165(4):397-9.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 3
5 Feb 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oral corticosteroids for poison ivy dermatitis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Oral corticosteroids for poison ivy dermatitis
John Goodall
CMAJ Feb 2002, 166 (3) 300;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Oral corticosteroids for poison ivy dermatitis
John Goodall
CMAJ Feb 2002, 166 (3) 300;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

Collections

  • Topics
    • Allergy
    • Drugs: immunologic

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire